Lansoprazole elevates the ratio of serum pepsinogen I v.s. Pepsinogen II

International Journal of Clinical Pharmacology Research

Volumn 17, Issue 4, 1997, Pages 127-132

  Matsukawa, Y ^a   Nishinarita, S ^a   Kaneko, M ^a   Takei, M ^a   Murakami, M ^a   Horie, T ^a   Kawamura, F ^a   Arakawa, Y ^a   Kuwayama, H ^b   Kurosaka, H ^c  

^a NIHON UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c Kurosaka Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; LANSOPRAZOLE; PEPSINOGEN I; PEPSINOGEN II;

ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; DUODENUM; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PROTEIN BLOOD LEVEL; STOMACH ANTRUM; STOMACH MUCOSA LESION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-ULCER AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; OMEPRAZOLE; PEPSINOGENS; PEPTIC ULCER;

EID: 7844220597     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Sanders S.W., Tolmar K.G., Greski P.A. The effect of lansoprazole, a new H:,K:-ATPase inhibitor, on gastric pH and serum gastrin. Alim. Pharm. Ther., 6. 359, 1992.
2. Barradell L.B., Faulds D., McTavish D, Lansoprazole. Drugs, 44, 225. 1992.
3. Nagata K , Satoh H., Iwai T., Shimoyama T., Tamura T. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob. Agents Chemother., 37, 769, 1993.
4. McGowan C.C., Cover T.L., Blaser M.J. The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism. Gastroenterolcgy, 107, 738, 1994.
5. Iwai T., Satoh H., Nakao M., et al. Lansoprazcle, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicroo. Agents Chemother., 35, 490, 1991.
6. Samloff I.M., Varis K., Ihamaki T., Siurala M., Rotter J.I. Relationship among serum pepsinogen I, serum pepsinogen II. and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology, 83, 204, 1982.
7. Miki K., Ichinose M., Kawamura N., et al. The significance of low pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects. Jpn. J. Can. Res., 80, 111, 1989.
8. Furuta T., Kaneko E., Baba S., Arai H., Futam H. Percentage changes in serum pepsinogens are useful as indices of eradication of Helicobacter pylori. Am. J. Gastroenterol., 92, 84, 1997.
9. Festen H.P.M., Thijs J.C., Lamers C.B.H.W., et al. Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels. Gastroenterology, 87, 1030, 1984.
10. Festen H.P.M., Tuynman H.A.R.E, Defize J., et al. Effect of single and repeated doses of oral omeprazole on gastric acid, pepsin secretion, fasting serum gastrin and serum pepsinogen I levels. Dig. Dis. Sci., 31, 561, 1986.
11. Biernond I., Crobach L.F.S.J., Jansen J.B.M.J., Lamers C.B.H.W. Effect of short-term omeprazole administration on serum pepsinogens in relation to fasting serum gastrin and gastric acid secretion. Eur. J. Clin. Pharmacol., 37, 345, 1989.
12. Baak L.C., Jansen J.B.M., Biemond I., Lamers C.B.H.W. Weekend treatment with 20 and 40 mg omeprazole: effect on intragastric pH, fasting and postprandial serum gastrin, and serum pepsinogens. Gut, 32, 977, 1991.
13. McColl K.E.L., Nujimi A.M., Dorrian C.A., MacDonald A.M.I., Fullarton G.M., Harwood J. Helicobacter pylori and hypergastrinemia during proton pump inhibitor therapy. Scand. J. Gastroenterol., 27, 93, 1992.
14. Meijer J.L., Jansen J.B.M.J., Biemond I., Lamers C.B.H.W. Effect of short-term administration of omeprazole on serum gastrin and pepsinogen in anterectomized patients. Digestion, 54, 139, 1993.
15. Jansen J.B.M.J., Klinkenberg-Knol E.C., Meuwissen S.G.M., et al. Effect of long-term treatment with omeprazoie on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology, 99, 621, 1990.
16. Miki K., Ichinose M., Furihata C., et al. Relationship between the location of gastric ulcer and the levels on serum group I and II pepsinogens. Jon. J. Gastroenterol., 80, 1726, 1983. (Eng. abstr)
17. Wu M.S., Wang H P., Wang J.T., Wang T.H., Lin J.T. Serum pepsinogen I and serum pepsinogen II, and the ratio of pepsinogen I/pepsinogen II in peptic ulcer diseases: With special emphasis on the influence of the location of ulcer crater. J. Gastroenterol. Hepatol., 10, 401, 1995.
18. Dotto P., Battaglia P.D., Franceschi M. Comparison of three different therapeutic regimens for eradicating Helicobacter pylon. Curr. Ther. Res., 53, 557, 1993.
19. Matsukawa Y., Nishinarita S., Horie T., Kurosaka H., Morita K., Mine T. Limited association of Helicobacter pylori in gastric ulcer patients with rheumatic disease. Brit. J. Rheumatol., 34, 1188, 1995.
20. Matsukura N , Onda M., Tokunaga A., Kato S., Yamashita K., Ohbayashi M. Detection of Helicobacter pylori DNA in gastric juice by the polymerase chain reaction: Comparison with findings in bacterial culture and the detection of tissue IgA and serum IgG antibodies against Helicobacter pylori. J. Gastroenterol., 30, 689, 1995.
21. Hirschowitz B.I. Pepsinogen: its origin secretion and excretion. Physiol. Rev., 37, 475, 1957.
22. Matsukawa Y., Nishinarita S., Horie T, et al. Novel ELISA kits for serum pepsinogens using polyclonal antibody: corelation with conventional RIA kits and clinical significance. Nihon Univ. J. Med., 38, 141, 1990.
23. Tanaka Y., Mine K., Nakai Y., Mishima N., Nakagawa T. Serum pepsinogen I concentrations in peptic ulcer patients in relation to ulcer location and stage. Gut, 32, 849, 1991.
24. Hunter F.M., Correa P., Fontnam E., Ruiz B., Sobhan M., Samloff I.M. Serum pepsinogens as markers of response to therapy for Helicobacter pylori gastritis. Dig. Dis. Sci., 38, 2081, 1993.
25. Wagner S., Haruma S., Glaoziwa V., et al. Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer. Am. J. Gastroenterol., 89, 1211, 1994.
26. Tokieda M., Kodarra K., Ito A., et al. Serum pepsinogen response to therapy for Helicobacter pylori associated gastroduodenal disease. Jpn. J. Gastroenterol., 92, 1825, 1995. (Eng. Abst.)
27. Gisbert J.P., Boixeda D., Vila T., deRafael L., Alvarez-Baleriola I., Martin-deArgila C. Is measurement of basal levels of serum pepsinogen II useful in proving the eradication of Helicobacter pylori by treatment? Med. Clin. Barc., 105, 561, 1995. (Eng. Abst.)
28. Kato K., Iwasaki A., Kawamura Y., et al. Usefulness of serum pepsinogen I/II ratio as a marker for evaluating H, pylori (Hp) eradication. Gastroenterology, 112, A169, 1997.
29. Oi M., Oshida K., Sugimura S. The location of gastric ulcer. Gastroenterology, 36, 45, 1959.